<DOC>
	<DOCNO>NCT00962039</DOCNO>
	<brief_summary>This study aim determine whether citalopram useful , well-tolerated , safe treatment child adolescent age 7 18 year functional abdominal pain . The study hypothesis citalopram well placebo produce clinical improvement reduction abdominal pain . It also hypothesize citalopram placebo differ term safety tolerability .</brief_summary>
	<brief_title>Anxiety Recurrent Abdominal Pain Children</brief_title>
	<detailed_description>This study aim determine relative efficacy , tolerability , safety citalopram treatment pediatric functional recurrent abdominal pain ( FAP ) child adolescent age 7 18 year , inclusive . The goal recruit randomize 100 subject citalopram placebo . Secondary aim include determine citalopram superior placebo reduce comorbid anxiety depressive symptom child adolescent FAP , explore potential mediator ( i.e. , anxiety , depression ) moderator ( e.g. , age , gender , referral primary specialty care ) treatment response , explore durability tolerability citalopram treatment 18 week follow completion double-blind treatment phase goal generate data useful development future study . The study novel conduct recruitment , assessment , treatment traditional medical setting . Limited exclusion criterion delivery study assessment intervention within routine practice setting provide considerably great external validity typical efficacy study . Study hypotheses : 1 . Citalopram superior placebo produce clinical improvement reduction abdominal pain . 2 . Citalopram placebo differ tolerability safety .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>At least 3 episode abdominal pain previous 3 month associate functional impairment absence explanatory physical disease follow clinically appropriate medical assessment . Age 7 year 0 month 18 year 11 month , inclusive , initial evaluation . Significant global functional impairment reflect score less 70 Children 's Global Assessment Scale Residing primary caretaker ( i.e. , parent , legal guardian , relative functioning parent , foster parent ) know child well least 6 month prior study entry legal authority consent participation . Physical disease sufficient explain subjective distress functional impairment suffer subject . FAP atypical feature : 1 . Abnormal abdominal rectal examination 2 . GI bleeding ( i.e. , hematest positive stool hematemesis ) 3 . History recurrent persistent fever associate abdominal pain 4 . Involuntary weight loss ( &gt; 5 % body weight ) previous 3 month 5 . Previous laboratory evidence suggest explanatory physical disease 6 . Persistent nighttime awakening due abdominal pain ( least per week &gt; 4 per month ) 7 . Persistent bilious vomit ( least per week &gt; 4 per month ) 8 . Abdominal pain exclusively associate menstruation 9 . Dysuria Physical disease citalopram monotherapy study participation might prove disadvantageous incompatible quality care , include bleed disorder characterize prolonged bleeding time , uncontrolled epilepsy , poorly control diabetes mellitus . Psychiatric problem disorder citalopram monotherapy study participation might prove disadvantageous incompatible quality care , include evidence child serious acute danger self others , anorexia nervosa , bulimia nervosa , schizophrenia , schizoaffective disorder , alcohol substance abuse/dependence , bipolar disorder . History mental retardation define full scale IQ &lt; 70 previous test participation special education placement mild severe mental retardation . Inadequate English speak ability child parent ( ) complete study measure and/or communicate study examiner . Adequate prior trial citalopram , escitalopram , another selective serotonin reuptake inhibitor venlafaxine . Adequate trial define least 4 week citalopram 20 mg/day , escitalopram 10 mg/day , fluoxetine 20 mg/day , fluvoxamine 100 mg/day , paroxetine 20 mg/day , sertraline 50 mg/day , venlafaxine 75 mg/day . Concurrent use nonsteroidal antiinflammatory drug ( NSAIDs ) , aspirin , anticoagulant medication . Treatment physical psychiatric illness initiate within prior 4 week escalate dosage intensity . History hypersensitivity citalopram serotoninsyndrome . Participation investigational drug study within thirty day study entry . Pregnancy Sexually active female subject refuse use medically accept method birth control study , engage unprotected sexual activity 30 day prior study .</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Abdominal Pain</keyword>
	<keyword>Anxiety</keyword>
</DOC>